Skip to main content
. 2022 Feb 22;10(2):e003978. doi: 10.1136/jitc-2021-003978

Figure 3.

Figure 3

Binding of mutated peptides to HLA-DRB1*01 molecules and immunogenicity. (A) Sequences of mutated peptides predicted as binders to HLA-DRB1*01 molecules with their corresponding WT version. (B) Mutated peptides were tested in binding assays at 100 µM using HOM2 cells. Results are expressed as Binding Score (BS). Peptides above the 0.5 BS threshold (horizontal bar) were considered positive. Results correspond to the mean of three different assays. (B) Mutated peptides were used to immunize HHD-DR1 mice (n=3 mice/peptide) and responses were measured by ELISPOT. (C) Immunogenic mutated peptides (n=3 mice/peptide) were tested against decreasing peptide concentrations of the mutated and WT versions.